Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cannabis Science a US Company specializing in cannabis formulation-based drug development and related consulting, has entered into a laboratory services agreement with ImmunoClin Corporation through its wholly-owned UK subsidiary, ImmunoClin, a healthcare company with over thirteen years' experience in providing premiere laboratory and related pre-clinical and clinical research services on a commercial scale.
Subscribe to our email newsletter
"With ImmunoClin’s track record in assisting biotech, pharma and food companies as well as public institutions in pharmaceutical and nutraceutical development projects, we are excited to initiate this long-term relationship between ImmunoClin and CBIS in the cannabinoid research field. We further benefit from the fact that ImmunoClin’s founder, Dr. Dorothy Bray, is a clinical development expert and serves at present as the Director, President and CEO of both Companies, thereby assuring smooth and effective collaboration," stated Mr. Mario S. Lap, Director and President of European Operations, Cannabis Science, Inc.
"With the contract in place, we intend to move quickly and efficiently to assist Cannabis Science in developing proprietary formulations to bring its cannabinoid based products to patients in need," said Khadija Benlhassan, Ph.D., Director and Chief Scientific Officer, ImmunoClin Corporation.
Cannabis Science anticipates that ImmunoClin will commence cannabinoid-based drug formulation at its laboratories within the coming weeks, including advanced development of Cannabis Science’s proprietary neurological drug, tentatively designated as "CS-Neuro-1". This contract complements the Company’s agricultural and research programs in Spain, Italy and other European countries.
"Cannabis Science looks forward to working with ImmunoClin in the development of CS-Neuro-1, CS-TATI-1, CS-S/BCC-1, and other products in the Cannabis Science pipeline that we strongly believe will improve the lives of people around the world," concluded Mr. Lap.